AltaThera is advancing the science of intravenous cardiovascular therapy — so physicians can act faster, patients recover sooner, and hospitals work smarter.
AltaThera Pharmaceuticals develops hospital-use intravenous drug therapies that give physicians the speed and precision to personalize cardiovascular treatment for patients with atrial fibrillation, atrial flutter, and life-threatening ventricular arrhythmias — including both adult and pediatric patients. Our intravenous approach enables rapid therapeutic assessment, more precise dosing, and — for appropriate adult patients — a faster route from initiation to discharge.
AFib affects an estimated 3 to 6 million people in the United States today — a number projected to reach 6 to 16 million by 2050.1 Patients face elevated risks of stroke, heart failure, and cardiovascular mortality, while health systems absorb the cost of inpatient antiarrhythmic drug initiation that can span multiple days.
Despite the scale of the need, access to optimized antiarrhythmic initiation remains uneven — and for some patient populations, a viable option has not existed at all. AltaThera is developing therapies to change that.
For adult patients, initiating oral sotalol requires a minimum three-day inpatient stay2 — impractical for patients in community settings and a strain on hospital bed availability.
Children with serious arrhythmias have historically had limited approved IV antiarrhythmic options, constrained by dosing complexity and scarce clinical data.
Over 1 million sotalol prescriptions are written annually in the U.S.3 — yet many patients cannot access optimized IV initiation.
AltaThera is based in Chicago, Illinois with a team across the country. At the heart of what we do is one of medicine’s most urgent and under-served challenges: cardiac arrhythmia. Every therapy we develop, every study we support, and every patient we reach reflects that commitment.